Allergen Immunotherapy in Atopic Dermatitis: light and shadow in
children.
Abstract
Atopic dermatitis (AD) is a chronic remitting-relapsing inflammatory
skin disorder. Due to the multifactorial pathogenesis, there are
numerous therapeutic management approaches, mainly based on symptomatic
treatments. In recent years Allergen Immunotherapy (AIT) has been
progressively advanced as targeted disease-modifying treatment of
allergic disease. The most recent guideline from the American Academy of
Dermatology concludes that data available do not support its use in AD.
The Joint Task Force and The European Academy of Dermatology suggest
that clinicians can consider AIT treatment in selected patients
characterized by aeroallergen sensitization, prevalently HDM, severe AD,
clinical exacerbation after exposure to the causative allergen.
Nevertheless, its role in AD is still under debate, especially in
children.